| 000 | 01825 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250518080553.0 | ||
| 264 | 0 | _c20210705 | |
| 008 | 202107s 0 0 eng d | ||
| 022 | _a1938-0690 | ||
| 024 | 7 |
_a10.1016/j.cllc.2019.11.015 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSteffen McLouth, Laurie E | |
| 245 | 0 | 0 |
_aPatient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice. _h[electronic resource] |
| 260 |
_bClinical lung cancer _c05 2020 |
||
| 300 |
_a255-263.e4 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 | _aCross-Sectional Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmune Checkpoint Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aImmunotherapy _xmortality |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPatient Reported Outcome Measures |
| 650 | 0 | 4 |
_aPractice Patterns, Physicians' _xstatistics & numerical data |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aSurvival Rate |
| 700 | 1 | _aLycan, Thomas W | |
| 700 | 1 | _aLevine, Beverly J | |
| 700 | 1 | _aGabbard, Jennifer | |
| 700 | 1 | _aRuiz, Jimmy | |
| 700 | 1 | _aFarris, Michael | |
| 700 | 1 | _aGrant, Stefan C | |
| 700 | 1 | _aPajewski, Nicholas M | |
| 700 | 1 | _aWeaver, Kathryn E | |
| 700 | 1 | _aPetty, W Jeffrey | |
| 773 | 0 |
_tClinical lung cancer _gvol. 21 _gno. 3 _gp. 255-263.e4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.cllc.2019.11.015 _zAvailable from publisher's website |
| 999 |
_c30498763 _d30498763 |
||